

Dr. Loui Madakamutil
Imcheck Therapeutics, Inc.



Loui Madakamutil is currently CSO of Imcheck Therapeutics that is pioneering in the discovery and development of Butyrophillins (BTNs) in oncology, autoimmunity and infectious diseases. Previously Loui was the Head of Preclinical development at Nektar Therapeutics and was responsible for the overall discovery strategy of Nektar to deliver novel immuno-modulatory medicines in several therapeutic areas including Cancer and Auto-inflammatory diseases. Loui was a Senior

Director and Lead for Rheumatology-DAS at Janssen Research Division where Loui was responsible for the discovery strategy and delivering portfolio assets from early ideas to proof of concept in humans in Rheumatic diseases. Loui held appointment as the Site Head of Immunology at Takeda Pharmaceuticals in San Diego, where over the 5-year period he has held positions of increasing responsibility in Drug Discovery and Early Development, and was responsible for driving Takeda's Discovery strategy in Immunology with a focus on inflammatory bowel disease (IBD) and Cancer Immunology. Loui also spent five years in Immunology discovery at Celgene in the Experimental Therapeutics Team where he worked on Apremilast and Revlemid to understand immunological MOA for these compounds. He has taken several large and small molecule compounds into Phase 1a. Loui did his Post-Doctoral training at the La Jolla Institute for Allergy and Immunology first with Eli Sercarz and then with Hilde Cheroutre. Loui has a PhD in applied immunology from University of Mumbai India and MS in Biochemistry.